Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHRUTI SINGH

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1619210143
CMS profile
751274
Location
DYER, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$7,143.14

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,675.00 3
Food and Beverage $2,048.75 94
Long term medical supply or device loan $299.10 3
Education $120.29 5

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHRUTI SINGH

NPI 1619210143 · CMS profile ID 751274

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DYER, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619210143?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHRUTI SINGH, NPI 1619210143, CMS profile ID 751274. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619210143?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SHRUTI SINGH, NPI 1619210143, CMS profile ID 751274. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619210143?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SHRUTI SINGH, NPI 1619210143, CMS profile ID 751274, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1619210143?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $7,143.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–105 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Karyopharm Therapeutics Inc. $29.8801/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845788901 CMS
Novartis Pharmaceuticals Corporation $99.7001/15/2021 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813270013 CMS
Pharmacyclics LLC, An AbbVie Company $26.3901/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781015173 CMS
AstraZeneca Pharmaceuticals LP $13.9401/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829423809 CMS
Eisai Inc. $22.5901/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817810997 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $626.10 21
PY2020 $1,418.37 55
PY2021 $7,143.14 105
PY2022 $25,007.30 132
PY2023 $60,915.75 185
PY2024 $43,107.03 169
PY2025 $17,768.46 101

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $699,965.23 44
PY2024 Principal investigator $27,650.58 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $101,273.08 12/31/2025 Non-covered Recipient Entity
Northwest Cancer Center - Dyer Clinic
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received No dispute reported 06/30/2026 1232924194
Principal investigator 1 ABBVIE INC. $15,200.00 12/18/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202531302
Principal investigator 1 ABBVIE INC. $5,206.78 12/04/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202527960
Principal investigator 1 ABBVIE INC. $42,359.79 12/04/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202527970
Principal investigator 1 ABBVIE INC. $5,206.78 11/05/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202522337
Principal investigator 1 ABBVIE INC. $5,902.47 10/09/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202513777
Principal investigator 1 ABBVIE INC. $2,195.00 09/10/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202510512
Principal investigator 1 ABBVIE INC. $6,598.16 09/04/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202509680
Principal investigator 1 Celgene Corporation $5,350.00 09/03/2025 Non-covered Recipient Entity
Northwest Cancer Center
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222305876
Principal investigator 1 Genmab U.S., Inc. $35,000.00 08/27/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235932430
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 08/27/2025 Non-covered Recipient Entity
Northwest Cancer Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246664196
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 08/27/2025 Non-covered Recipient Entity
Northwest Cancer Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246664200
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 08/27/2025 Non-covered Recipient Entity
Northwest Cancer Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246664202
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 08/27/2025 Non-covered Recipient Entity
Northwest Cancer Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246664204
Principal investigator 1 ABBVIE INC. $204.00 08/18/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202505015
Principal investigator 1 ABBVIE INC. $95.00 08/12/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202504251
Principal investigator 1 BioNTech SE $2,000.00 08/07/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTERS PC
BNT327-02 No dispute reported 06/30/2026 1249020335
Principal investigator 1 BioNTech SE $3,000.00 08/07/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTERS PC
BNT327-02 No dispute reported 06/30/2026 1249020337
Principal investigator 1 BioNTech SE $500.00 08/07/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTERS PC
BNT327-02 No dispute reported 06/30/2026 1249020339
Principal investigator 1 BioNTech SE $1,500.00 08/07/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTERS PC
BNT327-02 No dispute reported 06/30/2026 1249020343
Principal investigator 1 ABBVIE INC. $6,598.16 08/06/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202503109
Principal investigator 1 Karyopharm Therapeutics Inc. $35,000.00 07/29/2025 Non-covered Recipient Entity
Northwest Cancer Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246664198
Principal investigator 1 Celgene Corporation $4,725.00 07/23/2025 Non-covered Recipient Entity
Northwest Cancer Center
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222305902
Principal investigator 1 BioNTech SE $2,640.00 07/17/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTERS PC
BNT327-02 No dispute reported 06/30/2026 1249020341
Principal investigator 1 ABBVIE INC. $1,195.00 07/10/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202498030
Principal investigator 1 ABBVIE INC. $15,398.43 07/02/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202496651
Principal investigator 1 BioNTech SE $2,460.00 06/24/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTERS PC
BNT327-02 No dispute reported 06/30/2026 1249020321
Principal investigator 1 ABBVIE INC. $357.00 06/09/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202490663
Principal investigator 1 ABBVIE INC. $1,695.00 06/09/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202490665
Principal investigator 1 ABBVIE INC. $49,275.37 06/03/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202489471
Principal investigator 1 ABBVIE INC. $1,350.00 05/15/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202484939
Principal investigator 1 ABBVIE INC. $57,267.83 05/07/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202482379
Principal investigator 1 ABBVIE INC. $1,000.00 05/01/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202480699
Principal investigator 1 ABBVIE INC. $1,350.00 05/01/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202480701
Principal investigator 1 ABBVIE INC. $17,369.78 04/03/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202470274
Principal investigator 1 BioNTech SE $3,840.00 03/14/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTERS PC
BNT327-02 No dispute reported 06/30/2026 1249020301
Principal investigator 1 Celgene Corporation $35,000.00 03/03/2025 Non-covered Recipient Entity
Northwest Cancer Center
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222305934
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,400.00 02/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185542396
Principal investigator 1 ABBVIE INC. $30,775.00 02/04/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202443767
Principal investigator 1 ABBVIE INC. $1,100.00 02/04/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202443771
Principal investigator 1 ABBVIE INC. $9,119.32 02/04/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202443775
Principal investigator 1 ABBVIE INC. $30,775.00 02/04/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTER PC
M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202443781
Principal investigator 1 Celgene Corporation $38,575.00 01/24/2025 Non-covered Recipient Entity
Northwest Cancer Center
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1222305750
Principal investigator 1 AstraZeneca Pharmaceuticals LP $90,883.00 01/13/2025 Non-covered Recipient Entity
NORTHWEST CANCER CENTERS, PC
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185542394